O-304

O-304 is a small molecule AMPK activator.

Signaling Pathways >> Epigenetics >> AMPK

Signaling Pathways >> PI3K/Akt/mTOR >> AMPK

Research Areas >> Metabolic Disease

AMPK[1]

O-304 efficiently increases glucose uptake and reduces insulin resistance in skeletal muscle a primary cause of obesity-induced T2D. O-304 also reverses β-cell stress/dysfunction and induce β-cell rest. O-304 also increases energy expenditure and protects against diet induced obesity, fatty liver, hyperlipidemia and diabetes. CVD remains a major cause of death of T2 diabetics, and O-304 increases peripheral blood flow and left ventricular function, and acts as an “Exercise mimetic”. Thus, as an AMPK activator O-304 uniquely mitigates many of the metabolic and cardiovascular complications associated with the obesity epidemic. O-304 has the unique potential to increase glucose uptake and reduce insulin resistance in newly diagnosed T2 diabetics and as such prevent the associated β-cell hyperactivity/failure and progression of the disease[1].

[1]. Periodic Reporting for period 1-AMPK-DIAB (A small molecule AMP activated protein kinase (AMPK) activator, denoted O304, as a novelinnovative drug for the treatment of type 2 diabetes).

Dorsomorphin dihydrochloride | Acadesine (AICAR) | A-769662 | Phenformin (hydrochloride) | Bempedoic Acid | Flufenamic Acid | WZ 4003 | PF 06409577 | Dantron | 6-Gingerol | 7-Methoxyisoflavone | HTH 01-015 | YLF-466D | Ampkinone